DELIVER 预设分析:心衰病程与达格列净疗效
DELIVER 试验预设分析按心衰病程分层,比较患者特征、结局及达格列净疗效。病程越长者年龄更大、合并症和症状更多,主要结局发生率随病程延长而升高。达格列净获益在各病程组一致,绝对获益在病程最长组最大。
要点
- 心衰病程越长,主要结局发生率越高,>5 年组达 10.6/100 人年。
- 达格列净获益在各病程组一致,交互作用 P=0.41。
- 病程 >5 年组需治疗人数 24,≤6 个月组为 32。
核心结论
- 心衰病程越长,患者年龄更大、合并症和症状更多,主要结局发生率更高。
- 达格列净的获益在各心衰病程组中一致,绝对获益在病程最长组最大。
研究设计与样本
- DELIVER 试验的预设分析,按心衰病程分为 ≤6 个月、>6 至 12 个月、>1 至 2 年、>2 至 5 年、>5 年五组。
- 各组患者数分别为 1160、842、995、1569 和 1692 例。
- 主要结局为心衰恶化或心血管死亡的复合终点。
主要发现
- 主要结局发生率(每 100 人年)随病程延长而升高:≤6 个月 7.3(95%CI 6.3–8.4),>6 至 12 个月 7.1(6.0–8.5),>1 至 2 年 8.4(7.2–9.7),>2 至 5 年 8.9(7.9–9.9),>5 年 10.6(9.5–11.7)。
- 达格列净对主要结局的风险比:≤6 个月组 0.67(95%CI 0.50–0.91),>6 至 12 个月 0.78(0.55–1.12),>1 至 2 年 0.81(0.60–1.09),>2 至 5 年 0.97(0.77–1.22),>5 年 0.78(0.64–0.96),交互作用 P=0.41。
- 绝对获益在病程最长组最大,>5 年组需治疗人数为 24,≤6 个月组为 32。
关键数值与推荐
- 心衰病程分组界值:≤6 个月、>6 至 12 个月、>1 至 2 年、>2 至 5 年、>5 年。
临床怎么用
- 长期心衰且症状一般较轻的患者仍不稳定,仍可从钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)获益,不应认为为时已晚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: How patient characteristics and outcomes vary according to the duration of heart failure (HF) is unknown in individuals with mildly reduced or preserved ejection fraction. We compared these, and the efficacy and safety of dapagliflozin, according to the time from diagnosis of HF in a prespecified analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure). METHODS: HF duration was categorized as ≤6 months, >6 to 12 months, >1 to 2 years, >2 to 5 years, or >5 years. The primary outcome was the composite of worsening HF or cardiovascular death. The effect of treatment was examined by HF duration category. RESULTS: The number of patients in each category was as follows: 1160 (≤6 months), 842 (>6 to 12 months), 995 (>1 to 2 years), 1569 (>2 to 5 years), and 1692 (>5 years). Patients with longer-duration HF were older and had more comorbidities with worse symptoms. The rate of the primary outcome (per 100 person-years) increased with HF duration: ≤6 months, 7.3 (95% CI, 6.3 to 8.4); >6 to 12 months, 7.1 (6.0 to 8.5); >1 to 2 years, 8.4 (7.2 to 9.7); >2 to 5 years, 8.9 (7.9 to 9.9); and >5 years, 10.6 (9.5 to 11.7). Similar trends were seen for other outcomes. The benefit of dapagliflozin was consistent across HF duration category: the hazard ratio for the primary outcome in the ≤6-month group was 0.67 (95% CI, 0.50 to 0.91); >6 to 12 months, 0.78 (0.55 to 1.12); >1 to 2 years, 0.81 (0.60 to 1.09); >2 to 5 years, 0.97 (0.77 to 1.22); and >5 years, 0.78 (0.64 to 0.96; Pinteraction=0.41). The absolute benefit was greatest in longest-duration HF; the number needed to treat for HF >5 years was 24 versus 32 for ≤6 months. CONCLUSIONS: Patients with longer-duration HF were older, had more comorbidities and symptoms, and had higher rates of worsening HF and death. The benefits of dapagliflozin were consistent across HF duration. Even patients with long-standing HF and generally mild symptoms are not stable, and it is not too late for such patients to benefit from a sodium-glucose cotransporter 2 inhibitor. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03619213.
引用
- Kondo T, Jering KS, Borleffs CJW, et al. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2023. PMID: 36876483. doi:10.1161/CIRCULATIONAHA.122.062918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。